China Medical System (HKG:0867) obtained commercialization rights for its ABP-671 treatment for gout and high uric acid levels, according to a Monday filing with the Hong Kong Exchange.
CMS and Atom Therapeutics signed a commercialization agreement to sell the anti-gout drug in mainland China, Hong Kong, and Macau for 10 years, exetndable for another 10 years, the filing said.
Shares jumped 2% during Tuesday's trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments